Pollard JA, Guest E, Alonzo TA, Gerbing RB, et al. Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric KMT2A-Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531. J Clin Oncol 2021;39:3149-3160.
PMID: 34048275